Playing in RNA

Why M Ventures led $30M series A for RNA company Ribometrix

M Ventures, the strategic venture arm of Merck KGaA (Xetra:MRK), is adding another RNA company to its portfolio by leading a $30 million series A round for Ribometrix Inc.

Fellow new investors Amgen Ventures, Pappas Capital and

Read the full 379 word article

How to gain access

Continue reading with a
two-week free trial.